三諾生物(300298.SZ):認為無創血糖監測技術在當前不會對CGM行業產生較大沖擊
格隆匯5月25日丨三諾生物(300298.SZ)於2023年5月24日上午10:00接受機構調研,問答環節中,就“無創血糖監測技術會對CGM行業產生較大沖擊嗎?公司是怎麼看的?公司是否有研發生產無創技術類的產品?”,公司回覆稱,我們認為無創血糖監測技術在當前不會對CGM行業產生較大沖擊,當前CGM結合傳統BGM仍將是長期主流方法。血糖監測醫療市場對準確度要求極高,CGM作為血糖監測的有效方式,已被美國糖尿病協會在《糖尿病醫學診療標準》(2023版)中明確推薦糖尿病患者儘早並持續使用,所以CGM數據積累和算法升級已經被證明可以在波動階段保持準確性,目前市面上的無創血糖監測只能看到血糖變化趨勢,準確度無法達到醫用要求,無法用於臨牀糖尿病篩查診斷和治療依據,預計還需要較長的時間才能驗證。
公司AGEscan晚期糖基化終末產物熒光檢測儀是採用無創技術,通過檢測人體眼睛晶狀體中晚期糖基化終末產物(簡稱AGEs)積聚水平,實現糖尿病風險無創篩查,並通過統計海量臨牀大數據,建立糖尿病風險評估模型,無創預測未來糖尿病患病風險。由於AGEs的穩定、不可逆特性,因此高AGEs水平能夠反映更長時間異常血糖和氧化應激對身體的累積損傷,可作為糖尿病早期和併發症的預警信號。公司該產品已經獲得美國FDA認證。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.